Medofloran (Terbinafine)

Terbinafine blocks the fungal enzyme squalene epoxidase, which is essential for producing ergosterol, a key component of fungal cell membranes. By preventing ergosterol synthesis, the drug causes toxic buildup of squalene and weakens the membrane, leading to fungal cell death and resolution of the infection.

The dosage of Medofloran is individualized by the prescribing healthcare professional based on the specific infection, its severity, patient weight, renal and hepatic function, and other clinical factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for terbinafine in pregnancy and lactation are limited. Healthcare providers usually weigh the potential benefits against possible risks before prescribing it to pregnant or nursing women. Patients should discuss their situation with a physician to determine the most appropriate treatment.

To request Medofloran, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Medofloran (terbinafine) belongs to the allylamine class, which acts by inhibiting squalene epoxidase, whereas azoles such as itraconazole block lanosterol 14α‑demethylase. Allylamines often have a shorter treatment duration for nail infections and a lower potential for drug‑drug interactions compared with many azoles, though individual response varies.

Medofloran should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct light, and ensure the packaging remains tightly closed to maintain product stability.

Medofloran is taken orally, usually as a tablet, with or without food as directed by the prescriber. The exact schedule—such as once daily or another regimen—depends on the infection being treated and the clinician’s recommendation.

Serious adverse events, although rare, include liver injury (hepatotoxicity), severe skin reactions like Stevens‑Johnson syndrome or toxic epidermal necrolysis, hematologic abnormalities such as neutropenia, peripheral neuropathy, and anaphylactic reactions. Patients should seek immediate medical attention if they notice signs of these conditions.

Medofloran is contraindicated in individuals with known hypersensitivity to terbinafine or any component of the formulation. Caution is also advised for patients with severe liver or kidney impairment, and it should be avoided in those taking medications that have major interactions unless closely monitored.